Navigation Links
Dyadic International To Present At World Biofuels Markets
Date:3/4/2013

JUPITER, Fla., March 4, 2013 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries, announced today that its President and CEO, Mark Emalfarb , will be making a presentation at the World Biofuels Markets exhibition at the Beurs-World Trade Center in Rotterdam, The Netherlands during its Advanced Biofuels Session: Transformative Technologies, at 4:00 p.m. local time on March 13, 2013.

(Logo:  http://photos.prnewswire.com/prnh/20110621/CL06708LOGO )

All attendees of the World Biofuels Markets are welcome to visit Dyadic's stand located at Booth #E506 where Dyadic's leading scientists will be available to discuss specific applications of Dyadic's AlternaFuel® CMAX™ biofuels enzymes.

The World Biofuels Markets is Europe's largest biofuels congress and exhibition and one of the industry's premier events, supporting the world's development and search for alternative energy sources.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries. Please visit Dyadic's website at www.dyadic.com.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.


'/>"/>
SOURCE Dyadic International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Dyadic International To Announce Year-End 2012 Financial Results And Host Conference Call On Thursday, March 7, 2013
2. Dyadic International Upgraded By OTC Markets To "Current Information" Tier
3. 12th U.S. Patent Issued To Dyadic International
4. Dyadic International Reports 2012 Third Quarter Financial Results
5. Dyadic Netherlands To Develop Baking Enzymes For EU-Funded Research Project
6. Dyadic International to Announce Second Quarter 2012 Financial Results and Host Conference Call on Monday, August 13, 2012
7. Dyadic Demonstrates Industry-leading Biofuels Enzyme Performance
8. Dyadic International To Release First Quarter 2012 Financial Results And Host Conference Call
9. Dyadic International Launches FibreZyme® G5000 High Performance Powder Pulp and Paper Enzyme in Booth #1065 at Tissue World Americas Conference
10. Dyadic International Partners with Leading Provider of Nutritional Ingredient Solutions for Production of Food Enzymes
11. BioHealth Innovation, Inc. President & CEO Richard Bendis to Present at SXSW 2013 & 2013 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/15/2017)...  Trianni, Inc. („TRIANNI") gab heute bekannt, man ... über die Verwendung der The Trianni Mouse unterschrieben, ... Entdeckung monoklonaler Antikörper. Die Trianni Plattform ... das Janssen den Zugang zu einer ... für die schelle Isolierung vollständig menschlicher Therapeutika optimiert ...
(Date:2/15/2017)... 2017  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), ... fourth quarter and full year ended December 31, ... for Vanda as we continued to demonstrate strong ... exclusivity for Fanapt," said Mihael H. Polymeropoulos, M.D., ... pipeline with important 2017 milestones underscores Vanda,s commitment ...
(Date:2/15/2017)... Feb. 15, 2017 Windtree Therapeutics, Inc. (Nasdaq: ... developing aerosolized KL4 surfactant therapies for respiratory diseases, will ... presentation) at 8:00 AM EST on Thursday, February 16, ... clinical program, the recently announced closing of a $10.5 ... To participate in the live call and ...
(Date:2/15/2017)... ... February 15, 2017 , ... Diameter Health ... Diameter Health technology in the hands of Lantana analysts. The high-performance platform of ... and public health entities – all those mining value from clinical data – ...
Breaking Biology Technology:
(Date:2/7/2017)... 2017   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that the latest ... highly flexible and award winning eClinical solution, is now ... is a proven Software-as-a-Service (SaaS) clinical research technology ... but also delivers an entire suite of eClinical tools ...
(Date:2/7/2017)... 2017 Ipsidy Inc. ( www.ipsidy.com ... IDGS], ("Ipsidy" or the "Company") a provider of secure, ... is pleased to announce the following changes as part ... January 31, 2017, Philip D. Beck was ... President.  An experienced payment industry professional and public company ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute ... Larry Schlesinger as the Institute,s new President ... Biomed effective May 31, 2017. He is currently the Chair ... of the Center for Microbial Interface Biology at Ohio State ... as the new President and CEO of Texas Biomed," said ...
Breaking Biology News(10 mins):